<DOC>
	<DOCNO>NCT00000657</DOCNO>
	<brief_summary>To compare safety effectiveness orally administer didanosine ( ddI ) high dose orally administer zidovudine ( AZT ) patient develop exhibit progression AIDS dementia complex ( ADC ) previously intolerant AZT dose 1000 mg/day . HIV-infected AIDS patient may develop ADC cause damage nervous system . ADC may cause action AIDS virus nervous system , although similar problem cause infection AIDS virus lower body 's ability fight infection . It important determine whether symptom due ADC infection since treatment varies different condition . AZT show beneficial people ADC although effectiveness study small number patient . Studies suggest high dos AZT likely effective standard dose improve symptom ADC .</brief_summary>
	<brief_title>Comparison 2',3'-Dideoxyinosine ( Didanosine , ddI ) Zidovudine Therapy Patients With AIDS Dementia Complex</brief_title>
	<detailed_description>HIV-infected AIDS patient may develop ADC cause damage nervous system . ADC may cause action AIDS virus nervous system , although similar problem cause infection AIDS virus lower body 's ability fight infection . It important determine whether symptom due ADC infection since treatment varies different condition . AZT show beneficial people ADC although effectiveness study small number patient . Studies suggest high dos AZT likely effective standard dose improve symptom ADC . Patients randomly assign receive either oral ddI oral AZT .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>AIDS Dementia Complex</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chronic suppressive therapy herpes simplex virus , cytomegalovirus , Candida albicans , Salmonella . Prophylactic therapy Pneumocystis carinii pneumonia . Maintenance anticonvulsant therapy follow seizure context AIDS dementia complex . Isoniazid acceptable alternative therapy available . Judicious use benzodiazepine , tricyclic , antidepressant allow stable dose level obtain prior entry maintain throughout trial . In patient medically necessary initiate alter therapy drug initial 16 week study period , data use study . Metronidazole single course therapy exceed 14 day within consecutive 90day interval , first begin initiation study . Erythropoietin patient relevant Treatment IND . Symptomatic therapy ( analgesic , antihistamine , antiemetic , antidiarrheal agent ) . Allowed encourage : trimethoprim /sulfamethoxazole ( T/S ) sulfonamide . Patients must follow : Screened cause dementia . Stage 1 , 2 , 3 AIDS dementia complex . Estimated premorbid IQ least 70 . AntiHIV antibody HIV blood and/or cerebrospinal fluid . If prior history positive syphilis serology , treat appropriate course antibiotic ; , treatment administer prior pretreatment screen . Not previously show intolerance zidovudine ( AZT ) . Able ( parent and/or guardian able ) provide write consent . Allowed : Basal cell carcinoma , situ carcinoma cervix , Kaposi 's sarcoma without evidence visceral involvement require systemic chemotherapy . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Grade 3 neuropathy , base Neuropathy Targeted Symptom . Questionnaire , patient moderate abnormality indicative peripheral neuropathy include stocking loss sensation ( sharp pain , light touch , vibration ) , distal extremity weakness ( &lt; 4/5 ) , absent ankle jerk . History present past acute chronic pancreatitis . Active , symptomatic AIDSdefining opportunistic infection require ongoing maintenance therapy confound neurologic disease . Severe premorbid psychiatric illness include bipolar illness , schizophrenia , electroconvulsive therapy . Previous neurological disease unrelated HIV infection : multiple sclerosis , document stroke , degenerative disease . Patients chronic seizure disorder head injury exclude condition result functional impairment likely interfere evaluation . Concurrent previous central nervous system infection neoplasms reveal Computerized Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) scan cerebrospinal fluid analysis ( toxoplasmosis , primary metastatic Central Nervous System ( CNS ) lymphoma , progressive multifocal leukoencephalopathy , cryptococcal fungal meningitis , tuberculous Central Nervous System ( CNS ) infection , untreated neurosyphilis ) . Concurrent Medication : Excluded : Intravenous pentamidine . DHPG ( Ganciclovir ) coadministered . Monoamine oxidase ( MAO ) inhibitor , phenothiazine , butyrophenones , barbiturate , amphetamine . Oral acidify agent . Patients follow exclude : Neoplasms specifically allow . Grade 3 neuropathy . History present past acute chronic pancreatitis . Active , symptomatic AIDSdefining opportunistic infection . Requiring ongoing maintenance therapy confound neurologic disease . Conditions list Exclusion Coexisting Conditions . Prior Medication : Excluded within 30 day study entry : AntiHIV therapy zidovudine ( AZT ) . Biologic response modifier . Corticosteroids . Drugs toxic peripheral nerve . Investigative drug . Neurotoxic drug . Excluded : Dideoxycytidine ( ddC ) . Active alcohol drug abuse methadone maintenance sufficient , investigator 's opinion , prevent adequate compliance study therapy evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>AIDS Dementia Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>